ClinicalTrials.gg
CompletedNCT01865747METEORUpdated Apr 27, 2021Results posted

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

A Phase 3 interventional study of Cabozantinib tablets and Everolimus (Afinitor) tablets in Renal Cell Carcinoma, sponsored by Exelixis. Completed at 205 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-27.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
658
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies testing cabozantinib in Carcinoma, Renal Cell — 11 open to participants now, 23 under way, 4 of them phase 3. cabozantinib · Carcinoma, Renal Cell.

Enrollment
7th of 42
658 · median 44
Started
2013
with 1 other
Phase 3
6 of 42
2 open now
Registered
3rd of 42
by date
Lead sponsor
5 of 42
Exelixis

Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 3rd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 42 studies testing cabozantinib in Carcinoma, Renal Cell are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing cabozantinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • renal cell cancer
  • kidney
  • vascular endothelial growth factor receptor 2 (VEGFR2)
  • tyrosine kinase inhibitor
  • hepatocyte growth factor receptor protein (MET)
  • von Hippel-Lindau gene
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Select Inclusion Criteria:

  1. Documented histological or cytological diagnosis of renal cell cancer with a clear-cell component.
  2. as determined by the investigator.
  3. Must have received at least one VEGFR-targeting TKI (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib).
  4. Recovery from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  5. Adequate organ and marrow function.
  6. Sexually active fertile subjects(male and female)must agree to use medically accepted methods of during the course of the study and for 4 months after the last dose of study treatment.
  7. Female subjects of must not be pregnant at screening.

Select Exclusion Criteria:

  1. Prior treatment with everolimus, or any other specific or selective TORC1/PI3K/AKT inhibitor (eg, temsirolimus), or cabozantinib.
  2. Receipt of any type of small molecule kinase inhibitor (including kinase inhibitor) within 2 weeks before randomization.
  3. Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before randomization.
  4. Radiation therapy for bone within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Systemic treatment with radionuclides within 6 weeks before randomization. Subjects with ongoing complications from prior radiation therapy are not eligible.
  5. Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.
  6. Concomitant anticoagulation at therapeutic doses with oral anticoagulants or inhibitors.
  7. Chronic treatment with or other agents.
  8. Serious illness other than cancer.
  9. Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before randomization and from minor surgery at least 10 days before randomization.
  10. Pregnant or lactating females.
  11. Diagnosis of another within 2 years before randomization, except for superficial skin cancers, or localized, low grade tumors.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
658 participants (actual)

Study arms

  • Experimental
    Cabozantinib (XL184)

    Cabozantinib (XL184) 60 mg tablet once daily.

    Drug: Cabozantinib tablets

  • Active comparator
    Everolimus (Afinitor)

    Everolimus (Afinitor) 10 mg tablet once daily.

    Drug: Everolimus (Afinitor) tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    The primary analysis of PFS is the time from randomization to date of first documented tumor progression as determined by investigator (per RECIST 1.1 criteria) or death due to any cause, whichever occurred first. A Kaplan-Meier analysis was performed to estimate the median duration.

    Time frame: PFS is measured from the date of randomization until the date of first documented disease progression or date of death from any cause as determined by the Independent Radiology Committee (IRC) per RECIST 1.1, assessed for up to 17 months.

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from randomization to the date of death. Participants that had not died were censored at last known date alive. Median OS was calculated using Kaplan-Meier estimates. Interim analyses for OS occurred after 320 deaths (78% of the total OS events needed for final analysis).

    Time frame: OS was measured from the time of randomization until 320 deaths, approximately 28 months

  2. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is the number of participants with a best response of complete response (CR) or partial response (PR) divided by number of randomized participants. ORR was assessed by the Independent Radiology Committee (IRC) per RECIST 1.1 which was confirmed by a subsequent visit \>= 28 days later, and was analyzed in the Intent to Treat (ITT) population at the time of the primary analysis of Progression Free Survival (PFS). The data cutoff date was 22 May 2015.

    Time frame: ORR was assessed at 8 weeks post-randomization, every 8 weeks for 12 months, and every 12 weeks until date of disease progression or death, up to May 2015 (approximately 21 months)

07

Results

Posted Jul 18, 2017

Participant flow

First patient enrolled: 08 August 2013, Data cut off date: 22 May 2015

Overall Study (ITT)
Participant flow — Overall Study (ITT)
MilestoneCabozantinib (XL184)Everolimus (Afinitor)
Started330328
Completed13273
Not completed198255
Withdrew: Adverse event3231
Withdrew: Clinical deterioration2950
Withdrew: Lack of efficacy30
Withdrew: Protocol violation11
Withdrew: Physician decision52
Withdrew: Withdrawal by subject611
Withdrew: Sponsor decision01
Withdrew: Progressive disease122158
Withdrew: Reason not provided01
Primary Intent to Treat (PITT)
Participant flow — Primary Intent to Treat (PITT)
MilestoneCabozantinib (XL184)Everolimus (Afinitor)
Started187188
Completed5636
Not completed131152
Withdrew: Adverse event2120
Withdrew: Clinical deterioration1829
Withdrew: Lack of efficacy20
Withdrew: Protocol violation11
Withdrew: Physician decision42
Withdrew: Withdrawal by subject37
Withdrew: Progressive disease8292
Withdrew: Other01

Outcome measures

PrimaryProgression-free Survival (PFS)

The primary analysis of PFS is the time from randomization to date of first documented tumor progression as determined by investigator (per RECIST 1.1 criteria) or death due to any cause, whichever occurred first. A Kaplan-Meier analysis was performed to estimate the median duration.

Time frame:
PFS is measured from the date of randomization until the date of first documented disease progression or date of death from any cause as determined by the Independent Radiology Committee (IRC) per RECIST 1.1, assessed for up to 17 months.
Reported as:
Number · months
Progression-free Survival (PFS)
monthsCabozantinib (XL184)Everolimus (Afinitor)
Progression-free Survival (PFS)7.4 (5.6 to 9.1)3.8 (3.7 to 5.4)
Statistical analysis
  • Cabozantinib (XL184) vs Everolimus (Afinitor) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.58 · 95% CI 0.45 to 0.74The Log-Rank Test was stratified by the Memorial Sloan-Kettering Cancer Center (MSKCC) group and number of prior VEGFR TKIs.
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time from randomization to the date of death. Participants that had not died were censored at last known date alive. Median OS was calculated using Kaplan-Meier estimates. Interim analyses for OS occurred after 320 deaths (78% of the total OS events needed for final analysis).

Time frame:
OS was measured from the time of randomization until 320 deaths, approximately 28 months
Reported as:
Number · months
Overall Survival (OS)
monthsCabozantinib (XL184)Everolimus (Afinitor)
Overall Survival (OS)21.4 (18.7 to NA)16.5 (14.7 to 18.8)
Statistical analysis
  • Cabozantinib (XL184) vs Everolimus (Afinitor) · Log Rank · p = 0.0003 · Hazard ratio (hr): 0.66 · 95% CI 0.53 to 0.83The Log-Rank test was stratified by the Memorial Sloan-Kettering Cancer Center (MSKCC) risk group and number of prior VEGFR TKIs.
SecondaryObjective Response Rate (ORR)

Objective Response Rate (ORR) is the number of participants with a best response of complete response (CR) or partial response (PR) divided by number of randomized participants. ORR was assessed by the Independent Radiology Committee (IRC) per RECIST 1.1 which was confirmed by a subsequent visit \>= 28 days later, and was analyzed in the Intent to Treat (ITT) population at the time of the primary analysis of Progression Free Survival (PFS). The data cutoff date was 22 May 2015.

Time frame:
ORR was assessed at 8 weeks post-randomization, every 8 weeks for 12 months, and every 12 weeks until date of disease progression or death, up to May 2015 (approximately 21 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCabozantinib (XL184)Everolimus (Afinitor)
Objective Response Rate (ORR)173
Statistical analysis
  • Cabozantinib (XL184) vs Everolimus (Afinitor) · Cochran-Mantel-Haenszel · p = <0.0001

Adverse events

Collected over 08 August 2013 - 22 May 2015. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib (XL184)—131/331 (39.6%)328/331 (99.1%)
Everolimus (Afinitor)—139/322 (43.2%)270/322 (83.9%)
Most frequent serious events
Showing 10 of 214
Most frequent serious events
EventCabozantinib (XL184)Everolimus (Afinitor)
PneumoniaInfections and infestations6/33113/322
DyspnoeaRespiratory, thoracic and mediastinal disorders6/33113/322
AnaemiaBlood and lymphatic system disorders6/33112/322
Renal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/33111/322
Abdominal PainGastrointestinal disorders10/3312/322
Pleural EffusionRespiratory, thoracic and mediastinal disorders10/3316/322
PneumonitisRespiratory, thoracic and mediastinal disorders0/3318/322
DehydrationMetabolism and nutrition disorders3/3317/322
DiarrhoeaGastrointestinal disorders7/3312/322
NauseaGastrointestinal disorders7/3312/322
Most frequent other events
Showing 10 of 22
Most frequent other events
EventCabozantinib (XL184)Everolimus (Afinitor)
DiarrhoeaGastrointestinal disorders245/33188/322
FatigueGeneral disorders185/331149/322
NauseaGastrointestinal disorders164/33189/322
Decreased AppetiteMetabolism and nutrition disorders152/331108/322
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders139/33119/322
HypertensionVascular disorders122/33123/322
VomitingGastrointestinal disorders105/33144/322
Weight DecreasedInvestigations104/33139/322
ConstipationGastrointestinal disorders83/33161/322
DysgeusiaNervous system disorders78/33130/322

Baseline characteristics

Age, Customized
Age, Customized(participants)Cabozantinib (XL184)Everolimus (Afinitor)Total
<65196198394
65 to <7510794201
75 to <85263662
=>85101
Sex/Gender, Customized
Sex/Gender, Customized(participants)Cabozantinib (XL184)Everolimus (Afinitor)Total
Male253241494
Female7786163
Missing011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cabozantinib (XL184)Everolimus (Afinitor)Total
Ethnicity — Hispanic or Latino191837
Ethnicity — Not Hispanic or Latino278273551
Ethnicity — Unknown or Not Reported333770
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cabozantinib (XL184)Everolimus (Afinitor)Total
American Indian or Alaska Native000
Asian212647
Native Hawaiian or Other Pacific Islander000
Black or African American639
White269263532
More than one race000
Unknown or Not Reported343670
Geographic Region
Geographic Region(Participants)Cabozantinib (XL184)Everolimus (Afinitor)Total
Europe167153320
North America118122240
Asia Pacific394786
Latin America6612
Randomization Stratification Factors per CRF
Randomization Stratification Factors per CRF(Participants)Cabozantinib (XL184)Everolimus (Afinitor)Total
Prior VEGFR-TKI = 1235229464
Prior VEGFR-TKI ≥ 29599194
MSKCC risk factors = 0150150300
MSKCC risk factors = 1139135274
MSKCC risk factors = 2 or 3414384
Prior VEGFR-TKI = 1, MSKCC risk factors = 0102100202
Prior VEGFR-TKI = 1, MSKCC risk factors = 1107103210
Prior VEGFR-TKI = 1, MSKCC risk factors = 2 or 3262652
Prior VEGFR-TKI ≥ 2, MSKCC risk factors =0485098
Prior VEGFR-TKI ≥ 2, MSKCC risk factors = 1323264
Prior VEGFR-TKI ≥ 2, MSKCC risk factors = 2 or 3151732
Karnofsky performance status (KPS)
Karnofsky performance status (KPS)(Participants)Cabozantinib (XL184)Everolimus (Afinitor)Total
100 (normal activity)9974173
90 (normal activity, minor signs and symptoms)127142269
80 (normal w/effort, minor signs/symptoms)7590165
70 (unable to work, cares for self)292251
Heng Prognostic Criteria
Heng Prognostic Criteria(Participants)Cabozantinib (XL184)Everolimus (Afinitor)Total
0 adverse factors (favorable risk)6662128
1-2 adverse factors (intermediate risk)210214424
3-6 adverse factors (poor risk)5452106
08

Study locations

205 sites
  • Birmingham, Alabama, United States
  • Anchorage, Alaska 99503, United States
  • Gilbert, Arizona 85234, United States
  • Scottsdale, Arizona 85259, United States
  • Tucson, Arizona 85724, United States
  • Duarte, California 91010, United States
  • La Jolla, California 92093, United States
  • Los Angeles, California 90048, United States
  • Los Angeles, California 90095, United States
  • Vallejo, California 94589, United States
  • Aurora, Colorado 80045, United States
  • Denver, Colorado 80218, United States
  • New Haven, Connecticut 06520, United States
  • Washington, District of Columbia 20007, United States
  • Boca Raton, Florida 33486, United States
  • Miami, Florida 33136, United States
  • Miami, Florida 33176, United States
  • Orlando, Florida 06520, United States
  • Tampa, Florida 33612, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60637, United States
  • Iowa City, Iowa 52242, United States
  • Westwood, Kansas 66205, United States
  • Baltimore, Maryland 21201, United States
  • Baltimore, Maryland 21287, United States
  • Boston, Massachusetts 02215, United States
  • Ann Arbor, Michigan 48109, United States
  • Detroit, Michigan 48201, United States
  • Detroit, Michigan 48202, United States
  • Rochester, Minnesota 55905, United States
  • Saint Louis, Missouri 63110, United States
  • Las Vegas, Nevada 89148, United States
  • Albany, New York 12206, United States
  • New York, New York 10065, United States
  • Durham, North Carolina 22710, United States
  • Cleveland, Ohio 44106, United States
  • Cleveland, Ohio 44195, United States
  • Columbus, Ohio 43210, United States
  • Portland, Oregon 97213, United States
  • Portland, Oregon 97239, United States
  • Philadelphia, Pennsylvania 19111, United States
  • Pittsburgh, Pennsylvania 15232, United States
  • Charleston, South Carolina 29425, United States
  • Knoxville, Tennessee 37920, United States
  • Memphis, Tennessee 38120, United States
  • Nashville, Tennessee 37203, United States
  • Nashville, Tennessee 37232, United States
  • Austin, Texas 78731, United States
  • Bedford, Texas 76022, United States
  • Dallas, Texas 75246, United States
  • Fort Worth, Texas 76104, United States
  • Houston, Texas 77024, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84112, United States
  • Seattle, Washington 98109, United States
  • Vancouver, Washington 98684, United States
  • Yakima, Washington 98902, United States
  • La Plata, Buenos Aires B1900BAJ, Argentina
  • Mar Del Plata, B7600LTO, Argentina
  • Concord, New South Wales 2139, Australia
  • Darlinghurst, New South Wales 2010, Australia
  • Kogarah, New South Wales 2217, Australia
  • Port Macquarie, New South Wales, Australia
  • Randwick, New South Wales 2031, Australia
  • Wahroonga, New South Wales 2076, Australia
  • Westmead, New South Wales 2145, Australia
  • Milton, Queensland 4064, Australia
  • Wooloongabba, Queensland 4102, Australia
  • Adelaide, South Australia 5000, Australia
  • Hobart, Tasmania 7000, Australia
  • Bentleight East, Victoria 3165, Australia
  • Box Hill, Victoria 3128, Australia
  • Wodonga, Victoria 3690, Australia
  • Linz, Oberösterreich 4010, Austria
  • Wien, 1090, Austria
  • Wien, 1100, Austria
  • Bonheiden, Antwerpen 2820, Belgium
  • Brasschaat, Antwerpen 2930, Belgium
  • Bruxelles, Brussels 1000, Belgium
  • Leuven, Vlaams Brabant 3000, Belgium
  • Roeselare, West-Vlaanderen 8800, Belgium
  • Antwerpen, 2020, Belgium
  • Liege, 4000, Belgium
  • Calgary, Alberta T2N 4N2, Canada
  • Edmonton, Alberta T6G 1Z2, Canada
  • Vancouver, British Columbia V5Z 4E6, Canada
  • Winnepeg, Manitoba R3A 1R9, Canada
  • Halifax, Nova Scotia B3H 1V7, Canada
  • Hamilton, Ontario L8V 5C2, Canada
  • Kingston, Ontario K7L 5P9, Canada
  • London, Ontario N6A 4L6, Canada
  • Oshawa, Ontario L1G 2B9, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M5G 2N2, Canada
  • Montreal, Quebec H2L 4M1, Canada
  • Saskatoon, Saskatchewan S7N 4H4, Canada
  • Santiago, Chile

Showing the first 100 of 205 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Denize T, Farah S, Cimadamore A, Flaifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, Xie W, Choueiri TK, Signoretti S. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2022 Feb 15;28(4):748-755. doi: 10.1158/1078-0432.CCR-21-3088. PubMed 34921022 ↗
  • Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 7;21(1):904. doi: 10.1186/s12885-021-08630-w. Erratum In: BMC Cancer. 2021 Sep 15;21(1):1023. doi: 10.1186/s12885-021-08693-9. PubMed 34364385 ↗
  • Donskov F, Motzer RJ, Voog E, Hovey E, Grullich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2020 Feb;126:1-10. doi: 10.1016/j.ejca.2019.10.032. Epub 2019 Dec 27. PubMed 31887537 ↗
  • Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1. PubMed 31371341 ↗
  • Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29. PubMed 29377755 ↗
  • Escudier B, Powles T, Motzer RJ, Olencki T, Aren Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Lougheed JC, Bracarda S, Choueiri TK. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol. 2018 Mar 10;36(8):765-772. doi: 10.1200/JCO.2017.74.7352. Epub 2018 Jan 8. PubMed 29309249 ↗
  • Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5. PubMed 27279544 ↗
  • Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. PubMed 26406150 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of May 2015 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2013
First posted
May 31, 2013
Start
Jun 2013
Primary completionActual
May 22, 2015
CompletionActual
Jan 15, 2021
Results first posted
Jul 18, 2017
Last update
Apr 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01865747
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
May 31, 2013
Start date
Jun 2013
Primary completion
May 22, 2015
Completion
Jan 15, 2021
Results posted
Jul 18, 2017
Last update
Apr 27, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion